Citations

Showing 10 of 108083 citations.

Malignant Localized Fibrous Tumor of the Pleura
Strickland-Marmol, Leah B., Khoór, András , Williams, Charles C. , Robinson, Lary A.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 9 | Issue: 3 | Pages: 255-258

10.1177/107327480200900312 | PMID 12060824 Get It

Hepatic Surgery for Metastatic Gastrointestinal Neuroendocrine Tumors
Que, Florencia G., Sarmiento, Juan M. , Nagorney, David M.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 9 | Issue: 1 | Pages: 67-79

10.1177/107327480200900111 | PMID 11907468 Get It

An Update on Adjuvant Interferon for Melanoma
Gray, Richard J. , Pockaj, Barbara A. , Kirkwood, John M.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 9 | Issue: 1 | Pages: 16-21

10.1177/107327480200900103 | PMID 11907462 Get It

Burnout and Balance: How to Go the Distance in the 21st Century
Creagan, Edward T.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 11 | Issue: 4 | Pages: 266-268

10.1177/107327480401100411 | PMID 15284719 Get It

Applications of Endoscopic Ultrasonography in Pancreatic Cancer
Varadarajulu, Shyam, Wallace, Michael B. , Wallace, Michael B

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 11 | Issue: 1 | Pages: 15-22

10.1177/107327480401100103 | PMID 14749619 Get It

Background Accurate staging of pancreatic cancer is essential for surgical planning and for identification of locally advanced and metastatic disease that is incurable by surgery. Advances in endoscopic sonography (EUS), computed tomography (CT), and positron emission tomography have improved the accuracy of staging and reduced the number of incomplete surgical resections. Tissue acquisition is necessary in nonsurgical cases when chemoradiotherapy is considered. The complex regional anatomy of the pancreas makes cytologic diagnosis of malignancy at this region difficult without exploratory surgery. Although CT-guided fine-needle aspiration (FNA) is used for this purpose, reports of an increased risk of peritoneal dissemination of cancer cells and a false-negative rate of nearly 20% make this a poor choice. The ability to position the EUS-transducer in direct proximity to the pancreas by means of the stomach and duodenum, combined with the use of FNA, increases the specificity of EUS in detecting pancreatic malignancies. Methods The current literature regarding the accuracy of EUS with FNA in the evaluation of pancreatic cancer is reviewed. Results EUS accuracy ranges from 78% to 94% for tumor staging and from 64% to 82% for nodal staging. EUS also enables FNA of lesions that are too small to be identified by CT or MRI or too well encased by surrounding vascular structures to safely allow percutaneous biopsy. The accuracy for detecting invasion into the superior mesenteric artery and vein is lower than that for detecting portal or splenic vein invasion, especially for large tumors. EUS permits delivery of localized therapy such as celiac plexus neurolysis for pain control and direct intra-lesional injection of antitumor therapy. Conclusions EUS in combination with FNA is a highly accurate method of preoperative staging of pancreatic cancer, especially those too small to be characterized by CT or MRI, and it has the ability to obtain cytological confirmation of pancreatic cancer.
Molecularly Targeted Therapies for Breast Cancer
Hobday, Timothy J. , Perez, Edith A.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 12 | Issue: 2 | Pages: 73-81

10.1177/107327480501200202 | PMID 15855890 Get It

Background: The management of patients with localized and advanced breast cancer continues to evolve. Chemotherapy, endocrine therapy, and trastuzumab are effective therapies but leave considerable room for improvement. As the cellular aberrations inherent to cancer cells in general and breast cancer cells specifically are better understood, therapies to target specific cellular pathways continue to be developed with the goal of expanding available effective therapy through better patient selection. Methods: We conducted a computerized search of the medical literature as well as a manual search of selected meeting abstracts. Results: Several targeted therapies are in phase III clinical trials testing their promise in the treatment of breast cancer. Many other agents are completing phase I and II testing. An overview of the most promising agents in clinical development is discussed herein. Conclusions: Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future.
Novel Agents and Targets in Managing Patients with Metastatic Prostate Cancer
Tan, Winston , Tan, Winston W.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 13 | Issue: 3 | Pages: 194-198

10.1177/107327480601300306 | PMID 16885915 Get It

Background Docetaxel has recently been found to improve survival in patients with metastatic androgen-independent prostate cancer (AIPC). Chemotherapy as a first-line option leaves room for improvement, while second-line options are multiple and somewhat controversial. Methods Clinically relevant articles focusing on chemotherapy drugs for metastatic prostate cancer and their mechanism of action and efficacy were reviewed from January 2004 through April 2006. Results Docetaxel is the standard of care for AIPC. However, for doublets with docetaxel or second-line chemotherapy, multiple studies have shown interesting and promising results with calcitriol, thalidomide, bevacizumab, satraplatin, vaccines, ixabepilone, and atrasentan. Conclusions Docetaxel should be considered for first-line treatment of metastatic AIPC. Due to its progression-free survival of only 6 months, more effective drugs and drug combinations need to be developed to treat patients with AIPC. Combination treatments with docetaxel and other new agents are promising, but adequately powered phase III trials need to be conducted with survival as the principal endpoint for these promising drug combinations.
Cancer and Venous Thromboembolism: Scope of the Problem
Heit, John A.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 12 | Issue: 3_suppl | Pages: 5-10

10.1177/1073274805012003s02 | PMID 16179898 Get It

Caregiver Role Stress: When Families Become Providers
Teschendorf, Bonnie, Schwartz, Carolyn E. , Ferrans, Carol Estwing , O’Mara, Ann M., Novotny, Paul J. , Sloan, Jeff A.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 14 | Issue: 2 | Pages: 183-189

10.1177/107327480701400212 | PMID 17387304 Get It

Background In view of the large number of families engaged in caregiving, this study was initiated to describe informal cancer care provision from the perspective of the caregiver. Methods A professional data collection site was used to convene focus groups in four cities. Participants included 63 caregivers, 87% of whom were female, mean age of 56 years. Caregivers responded to an open-ended question regarding the challenges of providing care. The study utilized qualitative analysis of verbatim transcripts. Transcript coding with four independent raters, using an iterative process, achieved a high inter-rater reliability. Results The project elucidates self-reported concerns confronted in cancer caregiving. Five primary themes emerged: supportive care demands, emotional toll, impact on health status, coping strategies, and rewards and affirmation. Providing supportive care introduced a balancing act in caregivers’ lives as they attempted to address complex and overlapping roles. They felt alone in their decisions, were under-prepared for tasks they assumed, and tried to shield the care recipient. Conclusions This qualitative approach confirmed past research while identifying novel concepts related to maintaining well-being and a sense of purpose despite caregiving hardships. Some aspects of caregiver suffering were identified. Caregiver self-regulation strategies revealed by this work suggest ideas for psychosocial interventions caregivers could use to protect themselves and the care recipient from impending distress.
Evolution of Axillary Nodal Staging in Breast Cancer: Clinical Implications of the ACOSOG Z0011 Trial
Shah-Khan, Miraj G., Shah-Khan, Miraj, Boughey, Judy C.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 19 | Issue: 4 | Pages: 267-276

10.1177/107327481201900403 | PMID 23037494 Get It

Background Management of the axilla in breast cancer patients has evolved from routine axillary lymph node dissection (ALND) for all patients to a highly selective approach based on the assessment of the sentinel lymph nodes (SLNs) as well as tumor and patient characteristics. Although ALND continues to have an important role in staging and regional control for many breast cancer patients, recent trial results question the need for routine ALND in patients who have positive SLNs. Methods Not all axillary disease becomes clinically detectable or relevant with respect to recurrence and survival. Therefore, recent trends indicate that many surgeons have omitted ALND in subgroups of patients, particularly those with clinically node-negative, SLN-positive, early-stage breast cancer undergoing breast-conserving therapy with postoperative irradiation. This review explores trends in axillary management, focusing primarily on the clinical implications of the results from the American College of Surgeons Oncology Group (ACOSOG) Z0011 randomized controlled trial. Results According to the results of the ACOSOG Z0011 trial, the use of SLN dissection alone did not result in inferior survival compared with ALND in patients with limited SLN disease treated with breast-conserving therapy. This subgroup of women was spared the morbidity associated with ALND. However, several points of debate, including the smaller than anticipated sample size, the older study population, and the length of follow-up, suggest caution when applying these findings to all women with breast cancer. Conclusions Although the findings of ACOSOG Z0011 are impressive, in clinical practice they are applicable to a limited number of women with breast cancer: those with T1-2 primary tumors with clinically negative axilla and 1 to 2 positive SLNs undergoing breast-conserving surgery and adjuvant whole-breast irradiation. The next generation of clinical trials may answer some of the remaining questions regarding how best to manage the axilla in additional subsets of patients undergoing treatment of breast cancer.